
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech is a German biotechnology company with an 8% discounted cash flow-based valuation, a projected effective tax rate of 28% and a $33 billion firm value, mainly driven by its oncology pipeline, covid vaccine and its expected cash and trade receivables. Risks include potential negative data, slow market uptake and the recent spinoff of CEO Ugur Sahin and his spouse to start a new mRNA-focused biotech company, which we believe does not impact the intrinsic value of BioNTech's core operations. COVID revenues are expected to decline as the company shifts focus to its oncology pipeline, which we view as a positive for long-term growth and success.
Bears say
BioNTech is highly valued, but risks include slower than expected market uptake of its commercialized product, BioNTech might struggle to advance other programs in a timely manner such as negative data for BNT122, BNT111, BNT113, BNT116, BNT211, BNT316, BNT323, and BNT327, and partnership and/or M&A risks. Additionally, there is a possibility of long-term dilution risk.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares